Afamelanotide
Sponsors
Clinuvel Pharmaceuticals Limited, Clinuvel Europe Limited, Clinuvel, Inc., Clinuvel (UK) Ltd.
Conditions
Acne VulgarisAfamelanotide Evaluated as Skin DNA Repair Therapy in Healthy VolunteersArterial Ischemic StrokeErythropoietic ProtoporphyriaPatients Undergoing Photodynamic Therapy Using Porfimer SodiumPolymorphic Light EruptionSolar UrticariaVitiligo
Phase 1
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)
CompletedNCT01430195
Start: 2011-06-30End: 2012-11-30Updated: 2013-03-22
DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers
CompletedNCT05368857
Start: 2022-01-19End: 2023-02-01Updated: 2023-02-09
Phase 2
Phase II Solar Urticaria (SU) Pilot Study
CompletedNCT00859534
Start: 2008-12-31End: 2009-07-31Updated: 2009-09-15
Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)
CompletedNCT01097044
Start: 2010-04-30End: 2011-04-30Updated: 2019-10-28
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
CompletedNCT01382589
Start: 2011-09-30End: 2012-12-31Updated: 2013-03-22
Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium
CompletedNCT04425746
Start: 2008-08-05End: 2009-05-28Updated: 2021-10-01
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
CompletedNCT04525157
Start: 2014-06-06End: 2016-06-06Updated: 2023-09-22
Afamelanotide in Patients Suffering With Acne Vulgaris
CompletedNCT04943159
Start: 2010-08-24End: 2011-03-08Updated: 2021-10-26
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
CompletedNCT04962503
Start: 2021-06-03End: 2022-02-04Updated: 2023-04-11
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
NCT05159752
Start: 2021-10-19End: 2024-10-31Target: 6Updated: 2023-06-18
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
NCT05210582
Start: 2022-10-11End: 2023-08-31Target: 6Updated: 2023-02-09
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
NCT05370235
Start: 2022-03-28End: 2024-12-31Target: 6Updated: 2023-09-21
Phase 3
Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
CompletedNCT00979745
Start: 2009-09-30End: 2011-05-31Updated: 2021-10-12
Phase III Confirmatory Study in Erythropoietic Protoporphyria
CompletedNCT01605136
Start: 2012-05-31End: 2013-07-31Updated: 2019-09-19
Multicentre Phase III Erythropoietic Protoporphyria Study
CompletedNCT04053270
Start: 2007-05-31End: 2009-12-09Updated: 2019-10-10
A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
CompletedNCT04578496
Start: 2011-07-11End: 2014-02-27Updated: 2020-11-19
Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
CompletedNCT04704713
Start: 2010-05-05Updated: 2021-03-19